21 May 2013
Keywords: rigel, shares, hit, r112, ph, ii, failure
Article | 12 December 2005
Shares in the USA's Rigel Pharmaceuticals nose-dived 63% to $8.20 after the firm reported disappointing results from a comparative Phase II
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 December 2005
20 May 2013
© 2013 thepharmaletter.com